Lupus Low Disease Activity State Attainment in the Phase 3 TULIP Trials of Anifrolumab in Active Systemic Lupus Erythematosus
Ann Rheum Dis. 2023. doi: 10.1136/ard-2022-222748
Post-hoc anaylsis of TULIP trials shows that, compared with placebo, anifrolumab treatment was associated with earlier, more frequent, and more prolonged and sustained lupus low disease activity state (LLDAS).
In SLE, remission is seldom attained in clinical practice with standard of care medicines, and is attained even less frequently in clinical trials. However, the LLDAS is a validated treat-to-target (T2T) endpoint with the potential for practical application in the management of SLE. To this end, Morand, et al. investigated LLDAS attainment in anifrolumab-treated patients with moderate-to-severe SLE, highlighting its potential use in a T2T management approach.
